{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:39:44Z","timestamp":1780411184210,"version":"3.54.1"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2020.578824","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T05:45:24Z","timestamp":1600235124000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["In vitro Activity of Lefamulin Against the Common Respiratory Pathogens Isolated From Mainland China During 2017\u20132019"],"prefix":"10.3389","volume":"11","author":[{"given":"Shi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fupin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cmi.2017.06.010","article-title":"New and improved? a review of novel antibiotics for Gram-positive bacteria.","volume":"23","author":"Abbas","year":"2017","journal-title":"Clin. Microbiol. Infect"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1001\/jama.2019.15468","article-title":"Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial.","volume":"322","author":"Alexander","year":"2019","journal-title":"JAMA"},{"key":"B3","year":"2011","journal-title":"Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline (M43-A)."},{"key":"B4","year":"2018","journal-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically (M07)."},{"key":"B5","year":"2019","journal-title":"Performance standards for antimicrobial susceptibility testing (M100-S29)."},{"key":"B6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/14656566.2020.1714592","article-title":"An overview of lefamulin for the treatment of community acquired bacterial pneumonia.","volume":"21","author":"Falc\u00f3","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/cid\/ciz090","article-title":"Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) trial.","volume":"69","author":"File","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s40265-019-01219-5","article-title":"Leave it to lefamulin: a Pleuromutilin treatment option in community-acquired bacterial pneumonia.","volume":"79","author":"Lee","year":"2019","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02158-18","article-title":"Low prevalence of gram-positive isolates showing elevated lefamulin MIC results during the SENTRY surveillance program for 2015-2016 and characterization of resistance mechanisms.","volume":"63","author":"Mendes","year":"2019","journal-title":"Antimicrob. Agents Chemother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02161-18","article-title":"Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY antimicrobial surveillance program (2015\u20132016).","volume":"63","author":"Paukner","year":"2019","journal-title":"Antimicrob. Agents Chemother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1128\/aac.00358-13","article-title":"Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.","volume":"57","author":"Paukner","year":"2013","journal-title":"Antimicrob. Agents Chemother"},{"key":"B12","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1093\/jac\/dkz084","article-title":"Introduction: lefamulin and pharmacokinetic\/pharmacodynamics rationale to support the dose selection of lefamulin.","volume":"74","author":"Rodvold","year":"2019","journal-title":"J. Antimicrob. Chemother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/phar.2166","article-title":"Lefamulin: review of a promising novel pleuromutilin antibiotic.","volume":"38","author":"Veve","year":"2018","journal-title":"Pharmacotherapy"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02008-16","article-title":"In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant mycoplasma pneumoniae from the United States, Europe, and China.","volume":"61","author":"Waites","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2020.578824\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T05:45:25Z","timestamp":1600235125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2020.578824\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":14,"alternative-id":["10.3389\/fmicb.2020.578824"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2020.578824","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"article-number":"578824"}}